한글목차

만성폐쇄성폐질환(COPD) 치료제 시장 규모는 2023년부터 2033년까지 안정적인 성장세를 보일 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 10.3%에 달할 것으로 예상됩니다. 2023년 COPD 시장 규모는 주요 7개국 시장 전체가 115억 달러로 미국이 시장의 79.4%를 차지했습니다. EU 5개국이 20억 달러로 세계 COPD 시장의 17.5%를 차지했으며, 일본 COPD 시장은 2023년 3억 6,100만 달러로 시장의 3.1%를 차지했습니다.

예측 기간 동안 COPD 시장은 2033년 308억 달러 규모로 성장할 것으로 예상되며, 미국은 세계 시장의 78.9%를 차지하며 시장 규모는 243억 달러에 달할 것으로 예상됩니다. 미국은 CAGR 10.3%, 영국은 CAGR 15.3%로 이 기간 동안 가장 빠르게 성장하여 2033년 시장 규모가 8억 5,400만 달러에 달할 것으로 예상됩니다.

예측 기간 동안 사노피와 리제네론의 듀픽센트를 포함한 항호산구 생물학적 제제의 진입은 전체 COPD 매출에 기여하겠지만, 이들 치료제의 환자 점유율은 낮을 것으로 예상됩니다. 이들 치료제는 호산구가 많은 COPD 환자에게만 적응증을 가지고 있지만, 단가가 높은 편입니다.

이 보고서는 주요 7개국 COPD 시장을 조사하여 질병 개요, 역학 동향, 현재 치료법 및 미충족 수요, 파이프라인 동향 등을 정리하였습니다.

목차

제1장 만성폐쇄성폐질환 : 주요 요약

제2장 소개

제3장 질환 개요

• 병인과 병태생리학
• 2016 GOLD 분류 또는 병기결정 체계
• 2023년 새로운 GOLD 분류 시스템
• 증상
• 천식과 COPD의 중복

제4장 역학

• 질병 배경
• 위험요인과 병존질환
• 세계와 역사 동향
• 예측 조사 방법
• COPD 역학 예측
• 논의

제5장 질병 관리

• 진단과 치료 개요
• 미국
• EU
• 일본

제6장 현재 치료 옵션

제7장 미충족 수요와 기회 평가

• 개요
• COPD 진행을 역전시키는 질환 조절 치료
• 폐활량 측정에 대한 접근성과 트레이닝의 부족
• COPD 바이오마커
• 임상시험 설계 개선
• 조기 진단과 인식

제8장 연구개발 전략

• 개요
• 임상시험 설계

제9장 파이프라인 평가

• 개요
• 임상 개발중인 유망한 약제

제10장 파이프라인 평가 분석

• 개요
• 경쟁력 평가

제11장 현재 진출 기업과 향후 진출 기업

• 개요
• 거래 동향

제12장 시장 전망

• 세계 시장
• 미국
• EU 5개국
• 일본

제13장 부록

영문목차

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the COPD market through 2033.

Drug sales in the COPD drug market are expected to grow at a steady rate between 2023 and 2033, with an overall compound annual growth rate (CAGR) of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. The 5EU accounted for 17.5% of the global COPD market with an estimated value of $2.0 billion, and Japan's COPD market was estimated to be $361 million in 2023, accounting for 3.1% of the market.

Over the forecast period, the COPD market is anticipated to grow to a value of $30.8 billion in 2033, with the US anticipated to account for 78.9% of the global market and a market value of $24.3 billion. The US is forecast to grow at a CAGR of 10.3%, while the UK is anticipated to experience the fastest growth during this period with a CAGR of 15.3%, to reach a market value of $854 million by 2033.

Major drivers of growth in the COPD market during the forecast period include the following -

• The entry of anti-eosinophilic biologics, including Sanofi and Regeneron's Dupixent, over the forecast period will boost overall COPD sales despite the low patient share that these therapies will acquire. These therapies are only suitable for COPD patients with high levels of eosinophilia, but hold a high price per unit.
• Publication and changes made to the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) guidelines for therapies prescribed to GOLD E patients means an increase in inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) triple therapy use, as advised by the GOLD committee over the forecast period.
• The number of people with COPD and percentage of the drug-treated population will rise across the 7MM over the forecast period due to better awareness of COPD.

Major barriers to growth in the COPD market during the forecast period will include the following:

• The publication of GOLD guidelines and changes in the therapies given to GOLD E patients means there will be a decline in ICS/LABA being prescribed to patients over the forecast period.
• The introduction of an inhaler price cap by several pharmaceutical companies over the forecast period on various bronchodilators will mean overall sales may decrease over the forecast period, as therapies are cheaper.
• There may be low patient compliance to inhaler therapies due to the frequency of administration and dosing.

Key Highlights

• Report deliverables include a PDF report and Excel-based forecast model
• Forecasts includes the 7MM
• Forecasts covers from 2023-2033

Scope

• Overview of COPD - including epidemiology, disease etiology, management and Asthma-COPD Overlap (ACO).
• Topline COPD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
• Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM COPD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM COPD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Chronic Obstructive Pulmonary Disease: Executive Summary

• 1.1 The COPD market will show steady growth during the forecast period, reaching sales of $30.8 billion in 2033
• 1.2 GSK, AstraZeneca, and Sanofi/Regeneron competing for first place in 2033
• 1.3 COPD remains a market with high unmet need.
• 1.4 Lack of established biomarkers for COPD
• 1.5 Late-stage COPD pipeline therapies to target a niche population.
• 1.6 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming related reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 2016 GOLD classification or staging systems
• 3.3 New 2023 GOLD classification system
  • 3.3.1 US key opinion leader insights
  • 3.3.2 EU key opinion leader insights
  • 3.3.3 Japan key opinion leader insights
• 3.4 Symptoms
• 3.5 Asthma-COPD overlap
  • 3.5.1 Definition of asthma-COPD overlap
  • 3.5.2 Etiology and pathophysiology
  • 3.5.3 Key opinion leader insights on asthma-COPD overlap

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities.
• 4.3 Global and historical trends
• 4.4 Forecast methodology.
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods.
  • 4.4.3 Forecast assumptions and methods: total prevalent cases of COPD - 7MM.
  • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of COPD
  • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of COPD by severity - GOLD 2016 criteria using mMRC score
  • 4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of COPD by severity - GOLD 2016 criteria using CAT score.
  • 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of COPD by severity - GOLD 2023 criteria using mMRC/CAT scores.
• 4.5 Epidemiological forecast for COPD
  • 4.5.1 Total prevalent cases of COPD
  • 4.5.2 Diagnosed prevalent cases of COPD
  • 4.5.3 Age-specific diagnosed prevalent cases of COPD
  • 4.5.4 Sex-specific diagnosed prevalent cases of COPD
  • 4.5.5 Diagnosed prevalent cases of COPD by GOLD 2016 criteria using mMRC score
  • 4.5.6 Diagnosed prevalent cases of COPD by GOLD 2016 criteria using CAT score
  • 4.5.7 Diagnosed prevalent cases of COPD by GOLD 2023 criteria using mMRC score
  • 4.5.8 Diagnosed prevalent cases of COPD by GOLD 2023 criteria using CAT score
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 US
• 5.3 EU
• 5.4 Japan

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Disease-modifying treatments to reverse the progression of COPD
• 7.3 Lack of access and training of spirometry
• 7.4 Biomarkers for COPD
• 7.5 Improved clinical trial design
• 7.6 Earlier diagnosis and recognition

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Focus on type 2 inflammation with biologics
  • 8.1.2 Focus on treatment of exacerbators
• 8.2 Clinical trials design
  • 8.2.1 Defining the primary endpoints
  • 8.2.2 Innovative trial design
  • 8.2.3 Phenotyping in COPD trials

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - key opinion leaders interviewed for this report
  • 13.4.1 Key opinion leaders
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Managing Epidemiologist
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us